好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cereset Research Reduces Symptoms of Stress, Insomnia, and Anxiety in Healthcare Workers: a Randomized Clinical Trial
Aging, Dementia, and Behavioral Neurology
P9 - Poster Session 9 (8:00 AM-9:00 AM)
9-012
To test Cereset Research™ (CR), for reducing stress in healthcare workers (HCW).   

CR is a closed-loop, acoustic stimulation neurotechnology which in prior studies improved stress in other populations. We evaluate CR for stressed HCW.    
Adult HCW reporting elevated perceived stress levels (Perceived Stress Scale, PSS, ≥14) enrolled in this waitlist controlled randomized trial. Following consent and baseline measures (V1), participants were randomized to early intervention (EI) with 4, 36-minute sessions of CR (tones linked to brainwaves) or waitlist control condition (WC). Primary outcome assessment occurred 4-7 weeks (V3) later. The study was powered to detect a moderate clinically significant between-group difference in PSS score change at V3 (primary outcome). Secondary outcomes were Insomnia Severity Index (ISI) and Generalized Anxiety Disorder-7 (GAD-7). Control participants could opt to receive CR intervention following V3 assessment. Repeated measures ANOVA analyzed the longitudinal changes between groups.
Of 144 HCW enrolled, 86% were female, 40% nurses, mean age 44.7 (SD 11.6). Demographic and clinical characteristics were similar between groups. Ten dropped out, 5 per group. Mean PSS scores in EI were 21.4 (SD 4.8) at V1, 13.3 (SE 0.6) at V3, and in WC were 20.9 (SD 4.5) at V1, 19.9 (SE 0.6) at V3. The adjusted between-group PSS differences at V3 were EI -7.8 (SE 0.6), WC -1.2 (SE 0.6) (p<0.0001). Adjusted between-group differences were also significant for secondary outcome scores; ISI: EI -6.3 (SE 0.6), WC -0.5 (SE 0.6) (p<0.0001); GAD-7: EI -5.6 (SE 0.5), WC -1.3 (SE 0.5) (p<0001). The intervention was well tolerated.

This randomized, waitlist-controlled trial of noninvasive acoustic neuromodulation showed clinically meaningful, statistically significant improvement in perceived stress, anxiety and insomnia among stressed HCW. This intervention may be promising for implementation in health systems to reduce HCW stress.
Authors/Disclosures
Charles H. Tegeler, MD (Wake Forest School of Medicine)
PRESENTER 		Dr. Tegeler has nothing to disclose.
Catherine Tegeler (Wake Forest Sch of Med, Neurology) Ms. Tegeler has nothing to disclose.
Gregory Russell (Department of Biostatistics and Data Science) No disclosure on file
Dawn Kellar No disclosure on file
Kenzie Brown No disclosure on file
Suzanne Danhauer (Wake Forest University School of Medicine) No disclosure on file
Hossam A. Shaltout, PhD (Wake Forest School of Medicine) Dr. Shaltout has nothing to disclose.
Heidi Munger Clary, MD, MPH (Wake Forest University School of Medicine) Dr. Munger Clary has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Xenon. Dr. Munger Clary has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prova 好色先生. Dr. Munger Clary has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Munger Clary has stock in HCA Healthcare. Dr. Munger Clary has stock in Eli Lilly. Dr. Munger Clary has stock in Procter and Gamble. Dr. Munger Clary has stock in CVS. Dr. Munger Clary has stock in Johnson and Johnson. Dr. Munger Clary has stock in Novartis. Dr. Munger Clary has stock in Danahauer. The institution of Dr. Munger Clary has received research support from National Institute of Health. The institution of Dr. Munger Clary has received research support from Suzanne Marcus Collins Foundation. The institution of Dr. Munger Clary has received research support from Eysz, Inc. The institution of Dr. Munger Clary has received research support from Department of Defense. The institution of Dr. Munger Clary has received research support from Duke Endowment. Dr. Munger Clary has received personal compensation in the range of $500-$4,999 for serving as a speaker, Psychiatry Commission member with International League Against Epilepsy. Dr. Munger Clary has received personal compensation in the range of $0-$499 for serving as a Faculty with J. Kiffin Penry Epilepsy 好色先生 Programs. Dr. Munger Clary has a non-compensated relationship as a advisor, potential site PI with Liva Nova that is relevant to AAN interests or activities.